These results have been confirmed in plasma cell myeloma (PCM) and BL cell lines with translocated IGH/MYC and also in aggressive lymphomas with MYC overexpression not related to structural gene alterations, suggesting that this strategy may be useful in a broad spectrum of MYC driven tumors. This evidence concerns the gene MYC and plasma cell myeloma.